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Abstract  
Proliferation and differentiation of haematopoietic stem cells (HSCs) from umbilical cord 
blood at large scale will potentially underpin production of a number of therapeutic cellular 
products in development, including erythrocytes and platelets. However, to achieve 
production processes that are scalable and optimised for cost and quality, scaled down 
development platforms that can define process parameter tolerances and consequent 
manufacturing controls are essential.  
We have demonstrated the potential of a new, automated, 24×15mL replicate suspension 
bioreactor system, with online monitoring and control, to develop an HSC proliferation and 
differentiation process for erythroid committed cells (CD71+, CD235a+). Cell proliferation 
was relatively robust to cell density and oxygen levels and reached up to 6 population 
doublings over 10 days. The maximum suspension culture density for a 48 hour total media 
exchange protocol was established to be in the order of 107 cells/mL. This system will be 
valuable for the further HSC suspension culture cost reduction and optimisation necessary 
before the application of conventional stirred tank technology to scaled manufacture of HSC 
derived products.  
Keywords: Haematopoietic stem cells, Suspension culture, Bioreactor, Cell culture 
automation, Process development. 
Abbreviations: HSCs, haematopoietic stem cells; ambrTM, advanced microscale bioreactor; 
rpm, revolutions per minute; µ, mean; SEM, standard error of the mean; FITC, Fluorescein 
isothiocyanate;  dO2, dissolved oxygen; ANOVA, analysis of variance; SCF, stem cell factor; 
IGF-1, insulin-like growth factor 1; IL-3, interleukin 3; EPO, erythropoietin. 
Introduction 
Haematopoietic stem cells (HSCs) are multipotent cells with the ability to self-renew and 
differentiate into all blood cell lineages (Nielsen, 1999; Rizo et al., 2006). These properties 
confer a wide range of possible therapeutic applications for which umbilical cord blood 
constitutes a readily available cell source (Neildez-Nguyen et al., 2002). The development of 
such HSC-based products, i.e. red blood cells, has made significant progress in recent years 
(Douay and Andreu, 2007; Fujimi et al., 2008; Giarratana et al., 2005; Miharada et al., 2006). 
However, the number of cells required for a therapeutic dose will be up to the order of 1012 
cells per patient, necessitating a cell expansion process that sets a formidable production scale 
challenge for conventional bioprocessing formats. Intensification of commonly used static 
expansion systems (e.g. T-flasks, gas-permeable bags) is inherently limited by nutrient and 
gas concentration gradients, and a lack of on-line monitoring and control of key 
environmental conditions, limiting maximum supportable cell density (Liu et al., 2006). 
Understanding the feasibility of a scale-up approach in conventional stirred tank systems 
requires the use of low volume systems for  economic process design, development and 
optimisation, whilst retaining relevance to downstream manufacturing bioprocesses (Kirouac 
and Zandstra, 2008; Ratcliffe et al., 2011).   
Cell culture of HSCs to erythroid cells is currently costly, and scaled down processes are 
required for optimisation and cost reduction prior to scale up. Here we show the proliferation 
and erythroid commitment of HSCs at the lowest (and therefore most cost effective) 
suspension scale yet reported using an automated process development platform (the 
advanced microscale bioreactor workstation (ambr™), TAP Biosystems, Royston, UK) (Fig. 
1). The ability of this system to predict operating conditions at scale was recently 
demonstrated in terms of both cell productivity/growth and the physicochemical environment 
(Hsu et al., 2012). We show that ambr™ culture offers the control required to detect different 
cell responses to operating parameters, such as O2 tension and seeding density, and can 
support high density cell culture of HSCs. It will therefore form a valuable tool for 
optimisation and cost reduction of a complex and costly culture system prior to scale up.                                                                                                                                                                                                                   
Brief Methods 
Frozen CD34+ enriched umbilical cord blood cells (negative selection using RoboSep® 
automated cell separator, Stem Cell Technologies, Grenoble, France) were provided courtesy 
of Celgene Cellular Therapeutics (New Jersey, USA) after proliferation for 7 days in 2D 
culture conditions using StemSpan SFEM (serum-free expansion medium) (09650, StemCell 
Technologies) supplemented with the following cytokines and reagents for erythroid cell 
proliferation and differentiation; 100ng/mL SCF, 40ng/mL IGF-1, 5ng/mL IL-3, 3IU/mL 
EPO (R&D Systems, Oxford, UK), 40µg/mL Lipid and 1µM Dexamethasone (Sigma-
Aldrich, Poole, UK). Prior to cell defrost, ambrTM vessels were loaded with 14mL of this 
medium and stabilised at 37ºC, experimental dO2 level, and pH 7.4. Automated antifoam 
additions (20µL of 1% solution, Sigma-Aldrich) were made every 48h, or as required. 
Automated sodium bicarbonate additions (20µL of 1M solution, Sigma-Aldrich) maintained 
cultures at pH7.4 (trigger pH7.2, monitored every 2h). Cultures were initiated at several cell 
seeding densities as stated in the results tables (viability 96.27% ± 1.12% (µ±SEM)). 
Cultures were sampled for cell counting (Countess automated cell counter, Invitrogen, 
Paisley, UK) and metabolite analysis (Nova Bio-Profile Flex, Nova Biomedical, Runcorn, 
UK). Replacement of culture medium was conducted through centrifugation and re-
suspension of cells in fresh medium at intervals stated in results. Flow cytometry for 
erythroid lineage markers was performed after each expansion using CD235a-FITC or CD71-
FITC (BD Biosciences, Oxford, UK) conjugated antibodies and appropriate isotype controls 
according to manufacturer’s instructions. A  Cell Lab Quanta SC Flow Cytometer (Beckman 
Coulter, High Wycombe, UK) was used for analysis. Experimental runs were performed in 
triplicate, results expressed as the mean value of the data ± standard error of the mean 
(µ±SEM). Significance was determined using ANOVA (Minitab). 
Results and Discussion 
In order to determine feasibility of HSC proliferation in ambrTM, to identify conditions for 
rapid cell proliferation, and to establish time to the primary media exchange, cells were 
cultured under different oxygen tensions (dO2 5%, 15%)  and cell densities (2x104/mL, 
8x104/mL).  Slower proliferation observed after 5 days (5d) in all cultures indicated that the 
first media exchange should occur within this period. Both dO2 and cell density had a 
statistically significant effect on proliferation at  5d (P≤0.002), and there was a statistically 
significant interaction between the two parameters (P<0.001). Highest proliferation was 
achieved with 8x104 cells/mL seeding density and 15% dO2 (Exp 1, Table 1). A further 
culture was conducted with total media exchange after 4 days, and every 2 days thereafter, to 
further optimise around these identified operating parameters (Seeding density 4x104, 8x104, 
1.2x105/mL; dO2 7.5%, 15%, 21%). Lower seeding density increased proliferation after 8 
days culture (P<0.01) whilst O2 in this range was no longer significant (Exp 2, Table 1). The 
best growth conditions were continued to 10d (shown in bold) and achieved over 6 
population doublings (all growth curves shown in Figure 2). In order to establish the potential 
of the bioreactor to develop reduced cost processing strategies, complete medium 
replacement, 50% medium dilution, and cytokine addition without medium dilution were 
trialled. No significant differences in proliferation were observed after 6 days (3.16, 3.27, 
2.86 PDs respectively), but a small significant proliferative advantage was observed after 8 
days (4.4, 3.9, 3.7 PDs respectively). All data from experiment 2 was used to calculate 
coefficient of variation of 12.5% for replicate vessels indicating system robustness across the 
experimental range. At the end of all experiments the cells strongly expressed markers CD71 
(79-84%) and CD235a (51-64%) characteristic of erythroid lineage development and had 
viability of 90-97%, with no statistically significant differences between conditions. Cells 
processed in ambr™ were also capable of producing BFU-E colonies indicative of erythroid 
commitment (inset Figure 2). 
In order to establish the maximum supported cell density for a 48h media exchange 
suspension process, and therefore the most efficient production density range, HSCs were 
cultured without cell dilution. Over four successive cultures cells achieved densities of 0.98-
1.37x107 cells/mL. This was not dependent on the initial cell density (4x104-1.2x106/mL) 
indicating a density limit rather than an intrinsic cell proliferative limit. In order to determine 
if cytokine concentrations or reactor stir rates were limiting cell density these were both 
increased throughout culture (up to 3-fold and 1000rpm respectively). This had no significant 
effect on the terminal density and did not adversely affect viability. Nutrient consumption, 
metabolite production, pH, and dO2, were monitored during the culture to identify candidates 
for cell density limitations. pH and dO2 set levels did not deviate, indicating these factors are 
unlikely to limit cell density or growth at currently observed levels. As shown inset in Figure 
3, the dominant ammonia source was not related to cell culture density; pre-passage cell 
concentration increased by more than an order of magnitude, but the ammonia concentration 
range remained comparable and is therefore also unlikely to be the limiting factor for cell 
density at the levels observed.  
Glucose consumption per cell was calculated to identify required feed rates. Average early 
consumption rate (0.0166ng/cell/h, range 0.007-0.025ng/cell/h, calculated from first 4 hours 
of culture at day 6 in all experimental conditions) indicated complete depletion would occur 
in approximately 24 hours at a density at the order of 107 cells/mL assuming constant 
metabolic activity per cell. However, glucose (and glutamine) concentrations in high density 
culture did not reduce beneath 3.6g/L (and 2.5mmol) from fresh media levels of 4.5g/L (and 
4mmol). This indicates a substantial change in glucose consumption through the culture 
period and a requirement for more extensive metabolic studies. Lactate concentration in 
culture was usually beneath the limits of detection. However, it was measured at 0.1 to 1g/L 
in some of the higher density cultures (all >1×106 cells/mL) but showed no relationship to 
cell density beyond this. This lack of relationship indicates that lactate production per cell is 
highly variable at different points in culture. Lactate has been reported inhibitory to cell 
growth at the concentrations observed so it could be a factor in the reduced proliferation at 
higher densities or at the density limit (Hassell et al., 1991). 
Conclusion 
HSCs are good candidates for suspension culture production systems as many of the relevant 
cell types are naturally non-adherent. This should facilitate their clinical production due to the 
easy availability of large biopharmaceutical suspension bioreactors. The data reported here 
shows that HSCs can be cultured in the ambr™ platform at 10mL suspension scale, the 
lowest yet reported, and this can generate useful data for analysing parameters influencing 
cell growth, critical for necessary cost reduction studies. Metabolic data indicates that 
achieving densities in excess of those reported will be likely to require a perfused approach to 
cell produced factor removal and nutrient supply. This scaled down system of stirred tank 
operation can successfully support HSC proliferation and differentiation and therefore 
provide a valuable tool for further exploring the limits of HSC bioprocessing. 
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 Table 1 The average population doublings achieved under several seeding density and 
oxygen tension culture conditions in ambrTM (µ±SEM of triplicate cultures) identify the 
levels at which these parameters support rapid cell growth. 
  
Experiment/Culture 
duration 
Cell Density / 
mL 
Population Doublings @  dO2 
dO2  5% dO2  7.5% dO2  15% dO2  21% 
Exp 1: 5d 2×104 2.29 ± 0.10  2.09 ± 0.21  
8×104 2.24 ± 0.10  3.76 ± 0.16  
Exp 2: 8d 4×104  4.98 ± 0.07 4.97 ± 0.54 4.43 ± 0.40 
8×104   4.36 ± 0.02 4.10 ± 0.16 
1.2×105  4.11 ± 0.02  3.91 ± 0.07 4.30 ± 0.22 
Exp 2: 10d 4×104  6.31 ± 0.09 6.05 ± 0.23  
Fig. 1. The ambrTM automated suspension culture process development workstation: (1) 
Liquid handler, (2) Culture vessel control stations, (3) Pipette racks, (4) Reagent and sample 
plates. Culture vessel inset: (5) Vessel cap, (6) Gas supply filter, (7) Gas sparge tube, (8) 
Impeller, (9) pH sensor, (10) dO2 sensor. The workstation comprises 24 independent 
suspension culture bioreactors and offers precise control of the culture environment through 
online monitoring and automated control of temperature, pH, gassing, stirring, cell density 
and liquid handling.  
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Figure 2 Growth curves for variable cell seeding density (SD) and oxygen tension (O2) 
culture in ambrTM. Cells were cultured under the conditions described in Table 1 (Exp 2, 8 
days); Density: Low = 4×104/mL, Mid = 8x104/mL, High = 1.2x105/mL; dO2: Low = 7.5%, 
Mid =15%, High =21%. Inset graphs; cells express CD235a and CD71 after proliferation, 
indicators of erythroid lineage development, as shown by these typical flow cytometry 
profiles. Cells from the bioreactor also produced typical BFU-E colonies (inset) confirming 
erythroid lineage. 
 
 
  
Figure 3 Growth curves for HSC culture to high density in ambrTM without cell dilution. 
Cells were cultured under various conditions to high density. Start and End cell density of 
each culture are annotated. All conditions progressively increase to 3 fold normal cytokine 
supplementation and 1000 rpm stir rates. Higher seeding densities reduce growth rates but do 
not alter terminal density. The inset graph shows a lack of strong correlation between cell 
density and ammonia concentration (in this range) measured at the end of each culture period. 
 
